The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells

SIMPLE SUMMARY: Use of the antidiabetic drug metformin as a single antitumor agent has been disappointing in clinics. We sought to explain why cancer cells adapt to metformin treatment and to develop more effective drug combinations. We found that the antitumor actions of metformin involved a reduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Parisotto, Maxime, Vuong-Robillard, Nhung, Kalegari, Paloma, Meharwade, Thulaj, Joumier, Loick, Igelmann, Sebastian, Bourdeau, Véronique, Rowell, Marie-Camille, Pollak, Michael, Malleshaiah, Mohan, Schmitzer, Andréea, Ferbeyre, Gerardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688551/
https://www.ncbi.nlm.nih.gov/pubmed/36428689
http://dx.doi.org/10.3390/cancers14225597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688551/
https://www.ncbi.nlm.nih.gov/pubmed/36428689
http://dx.doi.org/10.3390/cancers14225597

Ejemplares similares